Canadian Stocks Climb 0.7%
Dow Jones2026/09/02 20:31This article was automatically generated by Dow Jones using technology from Automated Insights.
Stocks in Canada rose Wednesday, as the S&P/TSX Composite Index rose 0.7% to 36091.61.
Among large local companies, Endeavour Silver was the biggest leader during the session, surging 8.1%, and Highlander Silver surged 7.8%. AbraSilver Resource rounded out the top three movers, as shares surged 7.5%.
Celestica was the biggest laggard, tumbling 5.6%, followed by shares of Cronos Group, which fell 4.5%. Shares of Magellan Aerospace fell 3.7%.
U.S. stock indexes moved upward with the Dow Jones Industrial Average increasing 0.6%. Meanwhile, the S&P 500 Index added 0.5%, and the Nasdaq Composite Index increased 0.5%.
On the currency front, the WSJ Dollar Index dropped 0.2% to 95.70. The Canadian dollar strengthened 0.4% against the U.S. dollar to US$0.72.
In the bond markets, the 10-year Canadian government bond yield increased 5.64 basis points to 3.804%.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 02, 2026 16:31 ET (20:31 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
South Korea’s current account surplus in September exceeded 60 billions USD for the first time, with semiconductor exports becoming the main driver
Driven by booming semiconductor exports, South Korea's current account surplus in September surged to a record high.

CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading
CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.

AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response
According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test
Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).
